York profits from Genzyme, Alcon
By Suzy Kenly Waite
Tue Jan 11, 2011
See full 2010 performance information for Jamie Dinan’s 10 funds, which were all positive for the year.
As our recent cover story and 2010 Hedge Fund Report Card
noted, everybody loves Jamie Dinan, and it’s not
hard to see why. All ten of York Capital
Management’s funds were up in 2010, with the
largest, the $4.7 billion York Multi-Strategy, returning 7.11%
through December. The top performer was the $1.2 billion York
Select fund, which was up 16.06% (see the chart below for
performance on all York funds). York Multi-Strategy and York
Select in December both profited from positions in eye-care
company Alcon (the stock was one of York Select’s
top five positions that month). In mid-December, Swiss drug
ISSN: 2151-1845 / CDC10004H
TAKE A FREE TRIAL
The full contents of this article are available to Absolute Return subscribers and trialists only.
To continue reading please, take a free trial, subscribe or log in.
Subscribers have unlimited access to all current and archive content. Start your subscription today - click on the button below.